

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT


(10) International Publication Number
WO 01/68090 A1

- (51) International Patent Classification⁷: A61K 31/341, 7/16, A61P 31/04, 17/02, A61L 12/10, 2/16, C11D 3/48, A23K 1/17
- (74) Agent: F B RICE & CO; 139 Rathdowne Street, Carlton, VIC 3053 (AU).
- (21) International Application Number: PCT/AU01/00295
- (22) International Filing Date: 16 March 2001 (16.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PQ 6292 16 March 2000 (16.03.2000) AU
- (71) Applicant (for all designated States except US): UNISEARCH LIMITED - [AU/AU]; Rupert Myers Building, Level 2, Gate 14, Barker Street, University of New South Wales, Sydney, NSW 2052 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HOLMSTROM, Gerd, Pia, Carola [SE/AU]; 1/57 Govette Street, Randwick, NSW 2031 (AU). KJELLEBERG, Staffan [SE/AU]; 22 Goorawahl Avenue, La Perouse, NSW 2036 (AU).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/68090 A1

(54) Title: MICROBIAL INHIBITORY COMPOSITIONS



R₁, R₂, R₃ and R₄ is halogen.

(I)

(57) Abstract: The present invention provides an antimicrobial composition. The composition comprises a cell-permeabilising agent and at least one compound of general formula (I) wherein R₁ and R₂ are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic; R₃ and R₄ are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy; R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and "-----" represents a single bond or a double bond provided that at least one of

MICROBIAL INHIBITORY COMPOSITIONS

FIELD OF THE INVENTION

5 The present invention relates to compositions for use in inhibiting microorganisms.

BACKGROUND OF THE INVENTION

 It is known that a variety of furanone compounds possessing antifungal
10 and antimicrobial properties can be isolated from red marine algae *Delisea fimbriata*, *Delisea elegans* and *Delisea pulchra* (Reichelt and Borowitzka (1984) Hydrobiologia 116: 158-168). When first isolated, it was thought that these compounds may be suitable as antimicrobial agents for use in animals including humans. Unfortunately, it was found that most if not all of these
15 naturally occurring compounds were toxic to animal cells at the concentrations required to inhibit microorganisms and therefore unsuitable for many veterinary and medical applications.

 Gram positive bacteria are a major problem in hospitals, on skin, in the dental area, for heart transplants, catheters, and other biomedical implants.
20 Unfortunately, not all antimicrobial agents are active against Gram positive bacteria. Gram positive bacteria are also present in domestic areas including bathrooms, toilets and kitchens and can also cause a disease hazard for these sources. Accordingly, there is a need for more agents that are suitable to inhibit or kill these types of microorganisms in many varied situations
25 including domestic, veterinary and medical applications.

 Gram negative bacteria also pose a threat to human and animal health and new agents are also required to inhibit these microorganisms.

 Fungi are a major problem in hospitals, on skin, in the dental area, for heart transplants, catheters, and other biomedical implants. Fungi are also
30 present in domestic areas including bathrooms, toilets and kitchens and can also cause a disease hazard for these sources. Unfortunately, only a few antifungal agents are available which have broad spectrum of activity. Accordingly, there is a need for more agents that are suitable to inhibit or kill fungi in many varied situations including domestic, veterinary and medical
35 applications.


The present inventors have now made the surprising finding that active antimicrobial compositions which inhibit microbial growth can be prepared using a mixture of one or several furanone compounds, many of which were previously believed not to be suitable as antimicrobial agents.

5

SUMMARY OF THE INVENTION

In a first aspect, the present invention consists in an antimicrobial composition, the composition comprising a cell-permeabilising agent and at least one compound of general formula I:

10



- 15 wherein R_1 and R_2 are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;
 R_3 and R_4 are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy;
 20 R_3 or R_4 + R_2 can be a saturated or an unsaturated cycloalkane;
 and "-----" represents a single bond or a double bond provided that at least one of R_1 , R_2 , R_3 and R_4 is halogen.

Preferably, at least one of R_1 , R_2 , R_3 and R_4 is bromine. Most preferably, at least one of R_3 and R_4 is Br.

The term "alkyl" is taken to mean both straight chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, and the like. Preferably the alkyl group is a lower alkyl of 1 to 6 carbon atoms. The alkyl group may optionally be substituted by one or more groups selected from alkyl, cycloalkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkynyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino,

30

dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocyclyl, heterocycloxy, heterocyclamino, haloheterocyclyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as
5 phosphono and phosphinyl. The alkyl group may also be perfluorinated.

The term "alkoxy" denotes straight chain or branched alkyloxy, preferably C₁₋₁₀ alkoxy. Examples include methoxy, ethoxy, n-propoxy, isopropoxy and the different butoxy isomers.

The term "alkenyl" denotes groups formed from straight chain,
10 branched or mono- or polycyclic alkenes and polyene. Substituents include mono- or poly-unsaturated alkyl or cycloalkyl groups as previously defined, preferably C₂₋₁₀ alkenyl. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl,
15 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl, or 1,3,5,7-cyclooctatetraenyl.

20 The term "halogen" denotes fluorine, chlorine, bromine or iodine, preferably bromine or fluorine.

The term "heteroatoms" denotes O, N or S.

The term "acyl" used either alone or in compound words such as "acyloxy", "acylthio", "acylamino" or diacylamino" denotes an aliphatic acyl
25 group and an acyl group containing a heterocyclic ring which is referred to as heterocyclic acyl, preferably a C₁₋₁₀ alkanoyl. Examples of acyl include carbamoyl; straight chain or branched alkanoyl, such as formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl; alkoxycarbonyl, such as
30 methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl or heptyloxycarbonyl; cycloalkanecarbonyl such as cyclopropanecarbonyl cyclobutanecarbonyl, cyclopentanecarbonyl or cyclohexanecarbonyl; alkanesulfonyl, such as methanesulfonyl or ethanesulfonyl; alkoxysulfonyl, such as methoxysulfonyl or ethoxysulfonyl; heterocycloalkanecarbonyl;
35 heterocycloalkanoyl, such as pyrrolidinylacetyl, pyrrolidinylpropanoyl, pyrrolidinylbutanoyl, pyrrolidinylpentanoyl, pyrrolidinylhexanoyl or

thiazolidinylacetyl; heterocyclylalkenoyl, such as heterocyclylpropenoyl, heterocyclylbutenoyl, heterocyclylpentenoyl or heterocyclylhexenoyl; or heterocyclylglyoxyloyl, such as, thiazolidinylglyoxyloyl or pyrrolidinylglyoxyloyl.

5 As will be recognised by those skilled in the art the compounds of general formula I can exist as two isomers E and Z. It is intended that the general formulas depicted herein are not limited to a particular isomer and encompass both isomers either in the form of a racemic mixture or separated stereo isomers.

10 As used herein the term "cell-permeabilising agent" is used in its broadest sense and means an agent which increases the permeability of the cell membrane and/or cell wall of bacteria, yeast and fungi. A number of such agents are well known in the field and include certain antibiotics, aldehydes, biguanides, halogen releasing agents, peroxygens, phenols, bis-phenols, quaternary ammonium compounds, alcohols, glycols, ionic and non-ionic detergents.

15 Examples of suitable cell-permeabilising agents for combination with furanone compounds according to the present invention are set out in Table 1.


20

Table 1. Cell-permeabilising agents


Class of agent	Examples
Antibiotic	Polymyxin B
Aldehydes	Glutaraldehyde
	Formaldehyde
Biguanides	Chlorhexidine
Halogen releasing agents	Hypochlorous acid
	Iodine
Peroxygens	Hydrogen peroxide
Phenols	Chlorhexidine
	Peracetic acid
Bis-Phenols	Chlorinated bis-phenol fenticlor
	Hexachlorophene

Quaternary ammonium compounds	Cetyltrimethylammonium bromide (CTAB)
	Tetrabutylammoniumhydrogen sulfate
	Didecyltrimethylammonium bromide
	Cetylpyridium chloride
Alcohols	Toluene
Glycols	Polyethylene glycol (PEG)
Ionic detergent	Ethylenediaminetetraacetic acid (EDTA)
	Diamidines
	Citric acid
	Sodium lauryl sulfate (SDS)
Non-ionic detergent	TritonX-100
	Tween 80


In a preferred embodiment of the present invention compound is selected from the group consisting of



6



5



and combinations thereof.

For ease of reference these compounds will be referred to hereafter as compounds 2, 3, 19, 24, 25, 26, 27, 30, 33, 34, 45, 55, 56 and 57 as set out in Table 2.

Table 2.

5





Compound	Structure
2	
3	
19	
24	

Table 2 (cont)





Compound	Structure
25	
26	
27	
30	

Table 2 (cont)







Compound	Structure
33	
34	
45	
55	

Table 2 (cont)

Compound	Structure
56	
57	

The concentration of the compound or mixture of compounds in the composition is preferably between about 100 ng/ml and 100 µg/ml.

In use, the concentration of the furanone compound or mixture of furanone compounds in the presence of the cell-permeabilising agent required to have activity against bacteria is typically about 10 µg/ml.

The composition can be active against bacteria, yeasts and fungi.

Preferably, the cell-permeabilising agent is selected from antibiotics, chelating agents, ionic detergents, non-ionic detergents, organic solvents, quaternary ammonium compounds, and glycols.

Preferably, the antibiotic is polymyxin B, the chelating agent is N,N'-1,2-ethanediylbis[N-(carboxy-methyl)glycine] (EDTA), the ionic detergent is sodium lauryl sulfate (SDS) or cetyltrimethylammonium bromide (CTAB), the non-ionic detergent is TritonX-100 or Tween 80, the organic solvent is toluene, quaternary ammonium compound is cetylpyridinium chloride, and the glycol is polyethylene glycol (PEG).

The concentration of the cell-permeabilising agent can vary, depending on the agent used. For example, it has been found by the present inventors that 0.5 µg/ml of polymyxin B is particularly suitable. Similarly, 0.02% EDTA was found to be effective in a number of compositions.

In a second aspect, the present invention consists in a method of manufacturing an antimicrobial composition, the method comprising combining a compound of general formula I or a mixture of two or more such

compounds with a cell-permeabilising agent and a pharmaceutically acceptable diluent.

In a third aspect, the present invention consists in a method of inhibiting the growth of a microorganism, the method comprising exposing
5 the microorganism to an effective amount of an antimicrobial composition according to the first aspect of the present invention for sufficient time such that the microorganism is inhibited.

In a fourth aspect the present invention consists in a method of treating bacterial infection or decreasing the severity of symptoms of bacterial
10 infection in an animal, the method comprising administering to the animal an effective amount of the composition of the first aspect of the present invention.

The method includes *in vivo* and *in vitro* treatment of microorganisms.

The composition may be formulated as a pharmaceutical agent for human
15 and animal use, a topical agent for human and animal use, a disinfectant, an antiseptic, a mouth wash or rinse, a soap or cleaning agent or as part of animal feedstocks. The general formulations used for such products, in particular disinfectants, antiseptics, dentifrices, mouth washes or rinses, soaps, cleaning agents and supplements for animal feedstocks, is well known
20 in the art. The compositions of the present invention can be advantageously incorporated in such formulations, or alternatively the compositions of the present invention can further comprise ingredients which make up such products.

The composition of the present invention may also be used in the
25 cleaning a surface, such as a hard surface, woven surface or non-woven surface. Examples of surfaces in the cleaning of the composition of the present invention may be advantageously employed include toilet bowls, bath tubs, drains, countertops, food surfaces, airducts, air conditioners, carpets or cloths.

30 The composition of the present invention may also be used in paints so as to provide a microbial inhibitory property to the paint.

The compositions according to the present invention are particularly suitable for use in the treatment of cystic fibrosis, *Pseudomonas* infections, *Candida* infections, persistent burns infections, wound infections, contact
35 lens cleaning solutions, skin creams, treatment of oral infections, fungicides and a variety of other inhibitory products. It will be appreciated that the

compositions can be used or may be applicable in any situation where microbial inhibition is required.

The composition of the present invention can also be formulated in a topical dressing for burns.

- 5 The composition of the present invention can be used in environmental, sanitary, veterinary, or medical applications to inhibit the growth of microbes.

- Applications include, but are not limited to, inhibition of growth of microbial pathogens in environmental situations, reduction or prevention of
10 microbial colonisation of medical media including washing solutions, ointments and the like, inhibition of microbial attachment to surfaces and subsequent biofilm formation, as active ingredients in antiseptics and disinfectants.

- The compositions of the present invention will also find application in
15 preventing or inhibiting biofilm formation. In another embodiment the compositions will find application as washing solutions, particularly in contact lens cleaning compositions.

- The ability of composition of the present invention to inhibit the growth of a range of microbes provides a number of useful applications of
20 these compositions. In particular the compositions may be formulated for pharmaceutical use with human and non-human animals. In one embodiment of the invention the compositions are formulated for topical application for use, for example, in application to wounds and the like. In this regard they may be directly incorporated into bandages and the like.

- 25 In a further aspect the present invention consists in a method of treating *Pseudomonas* infection in an animal, the method comprising administering to an animal in need of such treatment a composition comprising tobramycin and at least one compound of general formula I as defined above.

- 30 In a preferred embodiment the *Pseudomonas* infection is a lung infection, in particular *P. aeruginosa* infection. In this embodiment it is preferred that the composition is administered by inhalation.

In a further preferred embodiment it is preferred that the animal is human. In one embodiment the animal is suffering from cystic fibrosis.

In a still further aspect the present invention consists in a composition for use in treatment of *Pseudomonas* infection, the composition comprising tobramycin and at least one compound of general formula I as defined above.

5 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

10

DETAILED DESCRIPTION

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and drawings.

15

Brief Description of Drawings

Figure 1. Growth of *Pseudomonas aeruginosa* in the presence of various furanones.

20

Figure 2. Screening of different furanones in the presence of polymyxin with *Escherichia coli*.

Figure 3. Growth of *Burkholderia cepacia* in the presence of polymyxin B and various furanones.

25

Figure 4. Growth of *Pseudomonas aeruginosa* against polymyxin B and various furanones.

Figure 5. Growth of *Pseudomonas aeruginosa* in the presence of EDTA and various furanones.

30

Figure 6. Growth of *Pseudomonas aeruginosa* in the presence of citric acid and furanone 30.

Figure 7. Growth of *Pseudomonas aeruginosa* in the presence of citric acid and furanone 34.

Figure 8. Growth of *Pseudomonas aeruginosa* in the presence of tetrabutylammoniumhydrogen sulfate and furanone 30.

35

Figure 9. Growth of *Pseudomonas aeruginosa* in the presence of didecdimethylammonium bromide and furanone 30.

Figure 10. Growth of *Pseudomonas aeruginosa* in the presence of Tween 80 and compound 30.

Figure 11. Growth of *Corynebacterium jeikeium* in the presence of furanone 2 and EDTA.

5 Figure 12. Growth of *Candida albicans* in the presence of EDTA and furanone 57.

EXAMPLE 1

Ten furanones (compounds 2, 3, 19, 30, 45, 55, 56, 24/25, 26/27 and
10 33/34) (see Table 2) were tested against growth of Gram negative bacteria in a combination treatment using a cell permeabilising agent (Polymyxin B and EDTA). As can be seen in Figure 1 the growth of *Pseudomonas aeruginosa* was not affected by the different furanones alone.

Growth of Gram negative bacteria is not generally affected by furanone
15 compounds alone. However, by simultaneously adding a compound which interferes with the permeability of the cell membrane, the present inventors have found that furanone compounds in combination with a permeability agent can prevent growth of microorganisms including bacteria, particularly Gram negative bacteria. In order to explore this concept, the antibiotic
20 polymyxin B was included in the initial round of experiments (see Figures 2, 3 and 4) involving the bacteria *Escherichia coli*, *Burkholderia cepacia* and *Pseudomonas aeruginosa*. The results from these experiments suggested that different furanone compounds target different Gram negative bacterial strains.

Different furanone compounds under test were applied at 10 µg/ml
25 (concentration of stock solution of furanone compound or mixture of compounds was 2 mg/ml) and polymyxin B was employed at concentrations which ranged from 0.3-1 µl/ml (stock solution was 10 mg/ml).

The results showed that compounds 45, 24/25 and 2 inhibited the
growth of *E. coli* for a time period of 8 hr (Figure 3) and compounds 45 and 30
30 prolonged the lag phase of growth of *B. cepacia* for 8-10 hr (Figure 4). Compound 30 was demonstrated to be the most active compound against *P. aeruginosa* (Figure 5). In addition, EDTA which also affects the permeability of the cell membrane was tested against growth of *P. aeruginosa* in combination with the different furanones. EDTA was added at a
35 concentration of 0.02%. The results demonstrated that compounds 30 and 56 were the most effective compounds in preventing growth (Figure 6) for this

organism. These results suggest that the mode of actions of polymyxin B and EDTA are different. It is possible that they differently allow for different furanones to penetrate the cell membrane.

5 EXAMPLE 2

Growth of *Pseudomonas aeruginosa* in the presence of citric acid, toluene, Tween 80 and two different quaternary ammonium compounds was further investigated. The tested furanones was furanone 30 and 34 at 10 µg/ml (concentration of stock solution of furanone compound was 10 mg/ml).
10 The used cell-permeability agents were employed at concentrations which ranged from 0.35-0.001%.

The results demonstrated that compound 34 in combination with citric acid prolonged the lag phase of growth with approximately 3 hours. Compound 30 + citric acid also prolonged the lag phase of growth however
15 not as strongly as compound 34. These results support the data from Fig 2-5 that different furanones in combination with a cell-permeability agent act differently on the growth of microorganisms. The two tested quaternary ammonium compounds in combination with furanone 30 inhibited the growth of *P. aeruginosa* with tetrabutylammoniumhydrogen sulfate being
20 slightly more active compared to didecyldimethylammonium bromide. The cell-permeability agent, Tween 80, gave a slight growth inhibition in combination with compound 30. Moreover, the growth of the Gram-positive bacteria, *Corynebacterium jeikeium*, was inhibited by compound 2 (100µg/ml) in combination with EDTA (0.02%). The lagphase of growth was prolonged
25 for 20 hr.

EXAMPLE 3


The yeast, *Candida albicans*, was tested in the presence of furanone 57 at 250 ng/ml. The used cell-permeability agent was EDTA (0.01%) and the
30 results are shown in Figure 12. The result demonstrated that compound 57 (250 ng/ml) inhibited the growth of *C. albicans* cells for 24 hrs. In combination with 0.01% EDTA the growth of the cells was inhibited for at least 32 hrs.

35 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the

specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:-

1. An antimicrobial composition, the composition comprising a cell-permeabilising agent and at least one compound of general formula I:



wherein R₁ and R₂ are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;
 10 R₃ and R₄ are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy;
 R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane;
 and "-----" represents a single bond or a double bond provided that at least
 15 one of R₁, R₂, R₃ and R₄ is halogen.

2. A composition as claimed in claim 1 in which at least one of R₁, R₂, R₃ and R₄ is bromine.




3. A composition as claimed in claim 1 or claim 2 in which at least one of R₃ and R₄ is Br.




20 4. A composition as claimed in any one of claims 1 to 3 in which cell-permeabilising agent is selected from the group consisting of antibiotics, aldehydes, biguanides, halogen releasing agents, peroxygens, phenols, bis-phenols, quaternary ammonium compounds, alcohols, glycols, ionic and non-ionic detergents.

25 5. A composition as claimed in claim 4 in which cell-permeabilising agent is selected from the group consisting of Polymyxin B, Glutaraldehyde, Formaldehyde, Chlorhexidine, Hypochlorous acid, Iodine, Hydrogen peroxide, Peracetic acid, Chlorinated bis-phenol fenticlor, Hexachlorophene, Cetyltrimethylammonium bromide (CTAB), Tetrabutylammoniumhydrogen
 30 sulfate, Didecyldimethylammonium bromide, Cetylpyridium chloride, Toluene, Polyethylene glycol (PEG), Ethylenediaminetetraacetic acid (EDTA),

Diamidines, Citric acid, Sodium lauryl sulfate (SDS), TritonX-100 and Tween 80


6. A composition as claimed in claim 5 in which cell-permeabilising agent is selected from the group consisting of Polymyxin B, EDTA, citric acid, tetrabutylammoniumhydrogen sulfate, didecyldimethylammonium bromide and Tween 80.
7. A composition as claimed in any one of claims 1 to 6 in which the compound is selected from the group consisting of





and combinations thereof.

8. A method of manufacturing an antimicrobial composition, the method comprising combining a cell-permeabilising agent with and a pharmaceutically acceptable diluent with at least one compound of general formula I:



wherein R_1 and R_2 are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally

interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₃ and R₄ are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy;

R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane;

- 5 and "-----" represents a single bond or a double bond provided that at least one of R₁, R₂, R₃ and R₄ is halogen;

9. A method as claimed in claim 8 in which at least one of R₁, R₂, R₃ and R₄ is bromine.

10. A method as claimed in claim 8 or claim 9 in which at least one of R₃
10 and R₄ is Br.


11. A method as claimed in any one of claims 8 to 10 in which cell-permeabilising agent is selected from the group consisting of antibiotics, aldehydes, biguanides, halogen releasing agents, peroxygens, phenols, bis-phenols, quaternary ammonium compounds, alcohols, glycols, ionic and non-
15 ionic detergents.

12. A method as claimed in claim 11 in which cell-permeabilising agent is selected from the group consisting of Polymyxin B, Glutaraldehyde, Formaldehyde, Chlorhexidine, Hypochlorous acid, Iodine, Hydrogen peroxide, Peracetic acid, Chlorinated bis-phenol fenticlor, Hexachlorophene,
20 Cetyltrimethylammonium bromide (CTAB), Tetrabutylammoniumhydrogen sulfate, Didecyldimethylammonium bromide, Cetylpyridium chloride, Toluene, Polyethylene glycol (PEG), Ethylenediaminetetraacetic acid (EDTA), Diamidines, Citric acid, Sodium lauryl sulfate (SDS), TritonX-100 and Tween 80


- 25 13. A method as claimed in claim 12 in which cell-permeabilising agent is selected from the group consisting of Polymyxin B, EDTA, citric acid, tetrabutylammoniumhydrogen sulfate, didecyldimethylammonium bromide and Tween 80.

- 30 14. A method as claimed in any one of claims 8 to 13 in which the compound is selected from the group consisting of


21




5



10





5 and combinations thereof.


15. A method of inhibiting the growth of a microorganism, the method comprising exposing the microorganism to an effective amount of an antimicrobial composition according to any one of claims 1 to 7 for sufficient time such that the microorganism is inhibited.

10 16. A method of treating microbial infection or decreasing the severity of symptoms of microbial infection in an animal, the method comprising administering to the animal an effective amount of the composition as claimed in any one of claims 1 to 7.

15 17. A method as claimed in claim 16 in which the microbial infection is *Pseudomonas* infection or *Candida* infections.

18. A method of treating *Pseudomonas* infection in an animal, the method comprising administering to an animal in need of such treatment a composition comprising tobramycin and at least one compound of general formula I:

20



wherein R_1 and R_2 are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;


- 5 R_3 and R_4 are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy;
 R_3 or $R_4 + R_2$ can be a saturated or an unsaturated cycloalkane;
 and "-----" represents a single bond or a double bond provided that at least one of R_1 , R_2 , R_3 and R_4 is halogen.

19. A method as claimed in claim 18 in which at least one of R_1 , R_2 , R_3 and R_4 is bromine.


20. A method as claimed in claim 18 or claim 19 in which at least one of R_3 and R_4 is Br.

21. A method as claimed in any one of claims 18 to 20 in which the compound is selected from the group consisting of


15



20




24



- 5
- 10 and combinations thereof.
22. A method as claimed in any one of claims 18 to 21 in which the *Pseudomonas* infection is *P. aeruginosa* infection.
23. A method as claimed in any one of claims 18 to 22 in which the *Pseudomonas* infection is a lung infection.
- 15 24. A method as claimed in any one of claims 18 to 22 in which the animal is human.
25. A method as claimed in claim 24 in which the animal is suffering from cystic fibrosis.

26. A composition for use in treatment of *Pseudomonas* infection, the composition comprising tobramycin and at least one compound of general formula I:



wherein R₁ and R₂ are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₃ and R₄ are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy;


R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane;

and "-----" represents a single bond or a double bond provided that at least one of R₁, R₂, R₃ and R₄ is halogen.



27. A composition as claimed in claim 26 in which at least one of R₁, R₂, R₃ and R₄ is bromine.

28. A composition as claimed in claim 26 or claim 27 in which at least one of R₃ and R₄ is Br.



29. A method as claimed in any one of claims 26 to 28 in which the compound is selected from the group consisting of




26




5



10






and combinations thereof.

30. A composition as claimed in any one of claims 26 to 29 in which the *Pseudomonas* infection is *P. aeruginosa* infection.
31. A composition as claimed in any one of claims 26 to 30 in which the *Pseudomonas* infection is a lung infection.
32. A composition as claimed in any one of claims 26 to 31 in which the animal is human.
33. A composition as claimed in claim 32 in which the animal is suffering from cystic fibrosis.
34. A contact lens cleaning preparation comprising the composition as claimed in any one of claims 1 to 7.
35. A washing solution comprising the composition as claimed in any one of claims 1 to 7.
36. A mouth wash preparation comprising the composition as claimed in any one of claims 1 to 7.
37. A disinfectant preparation comprising the composition as claimed in any one of claims 1 to 7.
38. A dentifrice comprising the composition as claimed in any one of claims 1 to 7.
39. An animal feedstock supplement comprising the composition as claimed in any one of claims 1 to 7.
40. A cleaning preparation comprising the composition as claimed in any one of claims 1 to 7.
41. A method of cleaning a surface which comprises applying to the surface the composition as claimed in any one of claims 1 to 7.
42. A method as claimed in claim 41 in which the surface to be cleaned is a hard surface, woven surface or non-woven surface.
43. A method as claimed in claim 41 or 42 in which the surface to be cleaned is a toilet bowl, bath tub, drain, countertop, food surface, air duct, air conditioner, carpet or cloth.

44. A topical dressing for burns comprising the composition as claimed in any one of claims 1 to 7.
45. A paint comprising the composition as claimed in any one of claims 1 to 7.
- 5 46. A skin cream preparation comprising the composition as claimed in any one of claims 1 to 7.


1/12

Figure 1. Growth of *Pseudomonas aeruginosa* in the presence of various furanones.




3/12

Figure 3. Growth of *Burkholderia cepacia* in the presence of polymyxin B and various furanones.




4/12

Figure 4. Growth of *Pseudomonas aeruginosa* against polymyxin B and various furanones.




5/12

Figure 5. Growth of *Pseudomonas aeruginosa* in the presence of EDTA and various furanones.




6/12

Figure 6. Growth of *Pseudomonas aeruginosa* in the presence of citric acid and furanone 30.




7/12

Figure 7. Growth of *Pseudomonas aeruginosa* in the presence of citric acid and furanone 34.




8/12

Figure 8. Growth of *Pseudomonas aeruginosa* in the presence of tetrabutylammoniumhydrogen sulfate and furanone 30.




9/12

Figure 9. Growth of *Pseudomonas aeruginosa* in the presence of didecyldimethylammonium bromide and furanone 30.




10/12

Figure 10. Growth of *Pseudomonas aeruginosa* in the presence of Tween 80 and compound 30.




11/12

Figure 11. Growth of *Corynebacterium jeikeium* in the presence of furanone 2 and EDTA.




12/12

Figure 12. Growth of *Candida albicans* in the presence of EDTA and furanone 57.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU01/00295

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : A61K 31/341, 7/16; A61P 31/04, 17/02; A61L 12/10, 2/16; C11D 3/48; A23K 1/17.												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)												
STN (File CA) Chemical Structure and Keywords: Microorg.; bacter.; antibacter.; phenotyp;												
Pub Med, Keywords: cell.; membrane, permeab.;												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
Y	Biofouling, Vol. 8(4), 1995, DeNys et al., "Broad spectrum ... assays", pages 259-71 See fig 1, page 261, page 265, paragraph "Inhibition....growth, and Page 267, table 3.	1-43										
Y	Pro. Int. Seaweed Symp., Vol. Date 1977, 9th, Issue title 9 1979, Fenical W. et al., "Antibiotics and ... (florideophyceae)", pages 387-400 See abst., page 387 and fig. 1, page 389.	1-43										
Y	Microbiology (Reading U.K.), Vol. 145(2), 1999, Manefield et al., "Evidence that... protein", pages 283-91. See abstract, in particular the last sentence and fig 1 page 285.	1-43										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 11 April 2001		Date of mailing of the international search report 24 April 2001										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  J.G. HANSON Telephone No : (02) 62832262										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU01/00295

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. Bacteriol., Vol. 180(2), 1998, Kjelleberg et al., "Extracellular... strain S14", pages 201-09. See abstract, fig 1 page 202 and page 207 column 1, paragraph commencing with "Furanones...".	1-43
Y	AU 49996/96 B (708962) (UNISEARCH LTD.) 26 September 1996. See page 2 lines 12-22, page 3 lines 8-12 page 4 lines 1-7, page 12 table 2 and figs. 1-3.	1-43
Y	WO 99/53915 A (UNISEARCH LTD.) 28 October 1999 See the document as a whole	1-43
Y	WO 99/54323 A (UNISEARCH LTD.) 28 October 1999 See claims 1, 21, 22 and 24	1-43
Y	Pub Med, Abst. PMID 338991 & Heppel, LA, et al., J. Supramol Struct. 1977; 6(3): 399-409 See Abst.	1-43
Y	PubMed, Abst. PMID 98103 & Anan'eva, EP, et al., Antibiotiki 1978 Jul; 23(7): 605-9 See Abst.	1-43
Y	PubMed, Abst. PMID 10030025 & Ayres, HM, et al., Lett. Appl. Microbiol. 1999 Jan; 28(1): 13-6 See Abst.	1-43
Y	PubMed, Abst. PMID 10478452 & Ziegelbauer, K, et al., Biosci Biotechnol. Biochem. 1999 Jul; 63(7): 1246-52 See Abst.	1-43
Y	PubMed, Abst. PMID 1624376 & Kimura, Y, et al., J. Antibiot (Tokyo) 1992 May; 45(5): 742-9 See Abst.	1-43

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU01/00295

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
AU	49996/96	WO	9629392	BR	9607661	EP	815201
		NZ	303630	CA	2215797	CN	1185173
WO	9953915	AU	33224/99	EP	1071416		
WO	9954323	AU	33225/99	EP	1071677		
END OF ANNEX							